Trend Report for Global Pharma, Medical & Biotech Released

April 7, 2017

Mergermarket, a media company reporting financial news and analysis, announced its Global Pharma, Medical & Biotech (PMB) trend report for Q1 (first quarter) of 2017. The report analyzes PMB global mergers and acquisitions (M&A) from Q1-Q4 2016 to Q1 2017.

Mergermarket, a media company reporting financial news and analysis, announced its Global Pharma, Medical & Biotech (PMB) trend report for Q1 (first quarter) of 2017. The report analyzes PMB global mergers and acquisitions (M&A) from Q1-Q4 2016 to Q1 2017.

Findings indicate that the first quarter of 2017 saw a decline (-14.8%) from last year’s Q1, with 314 deals worth $76 billion, but overall Q1 2017 did as well, if not better, than the last three quarters of 2016.

A major influence was Johnson & Johnson’s acquisition of Actelion Pharmaceuticals for $29.6 billion. The deal accounted for 39% of global PMB, with 76.9% of that benefitting Europe’s overall PMB value. Europe documented 98 deals worth $38.5 billion-a 132.7% increase over Q1 of last year.

Still, biotech took the lead with 42 deals worth $38.8 billion, increasing value 1,021.7% in comparison to last year’s first quarter.

To view the full report, click here.